BioVersys to Announce Half-Year 2026 Financial Results and Business Update

BioVersys AG, a clinical stage biopharmaceutical company based in Basel, Switzerland, plans to release its half-year 2026 financial results on September 9, 2026. The company is specialized in the development of novel antibacterial products targeting multi-drug resistant bacteria. Along with the financial report, BioVersys will offer a business update.

On the day of the announcement, BioVersys will issue a press release at 7:00 AM CET. A conference call and webcast will follow at 2:00 PM CET, allowing investors, analysts, and journalists to engage directly with company management. The session will cover financial details, business updates, and strategic outlook.

BioVersys is advancing significant R&D programs, including the BV100 for Acinetobacter baumannii and alpibectir for tuberculosis, the latter in collaboration with GlaxoSmithKline and the University of Lille.